Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Respiratory syncytial virus infection in children with congenital heart disease: global data and interim results of Korean RSV-CHD survey

  • Jung, Jo-Won (Division of Pediatric Cardiology, Department of Pediatrics, Ajou University School of Medicine)
  • 투고 : 2011.04.25
  • 심사 : 2011.05.04
  • 발행 : 2011.05.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Respiratory syncytial virus (RSV) is a main cause of hospitalization for bronchiolitis and pneumonia in infants worldwide. Children with hemodynamically significant congenital heart disease (HS-CHD), as well as premature infants are at high risk for severe RSV diseases. Mortality rates for CHD patients hospitalized with RSV have been reported as about 24 times higher compared with those without RSV infection. Recently with advances in intensive care, mortality rates in CHD patients combined with RSV have decreased below 2%. The requirements of intensive care and mechanical ventilation for CHD patients with RSV infection were still higher than those without RSV infection or with non-CHD children. RSV infection has frequently threatened CHD infants with congestive heart failure, cyanosis, or with pulmonary hypertension. As a progressive RSV pneumonitis in those infants develops, the impairment of oxygen uptake, the breathing workload gradually increases and eventually causes to significant pulmonary hypertension, even after the operation. Preventing RSV infection as much as possible is very important, especially in infants with HS-CHD. A humanized monoclonal antibody, palivizumab, has effective in preventing severe RSV disease in high-risk infants, and progressive advances in supportive care including pulmonary vasodilator have dramatically decreased the mortality (<1%). Depending on the global trend, Korean Health Insurance guidelines have approved the use of palivizumab in children <1 year of age with HS-CHD since 2009. Korean data are collected for RSV prophylaxis in infants with CHD.

키워드

참고문헌

  1. Howard TS, Hoffman LH, Stang PE, Simoes EA. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J Pediatr 2000;137:227-32. https://doi.org/10.1067/mpd.2000.107525
  2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375:1545-55. https://doi.org/10.1016/S0140-6736(10)60206-1
  3. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360:588-98. https://doi.org/10.1056/NEJMoa0804877
  4. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400. https://doi.org/10.1056/NEJM198208123070702
  5. Wright M, Piedimonte G. Respiratory syncytial virus prevention and therapy: Past, present, and future. Pediatr Pulmonol 2011;46:324-47. https://doi.org/10.1002/ppul.21377
  6. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86. https://doi.org/10.1001/jama.289.2.179
  7. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7. https://doi.org/10.1542/peds.102.3.531
  8. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40. https://doi.org/10.1067/S0022-3476(03)00454-2
  9. Cooper DS, Jacobs JP, Chai PJ, Jaggers J, Barach P, Beekman RH, et al. Pulmonary complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal Database Committee for Pediatric and Congenital Heart Disease. Cardiol Young 2008;18 Suppl 2:215-21. https://doi.org/10.1017/S1047951108002941
  10. Feltes TF, Groothuis JR. Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol Young 2005;15:266-73. https://doi.org/10.1017/S1047951105000557
  11. Cabalka AK. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Pediatr Infect Dis J 2004;23(1 Suppl):S41-5. https://doi.org/10.1097/01.inf.0000108220.94201.1a
  12. Altman CA, Englund JA, Demmler G, Drescher KL, Alexander MA, Watrin C, et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433-8. https://doi.org/10.1007/s002460010103
  13. Navas L, Wang E, De Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992;121:348-54. https://doi.org/10.1016/S0022-3476(05)90000-0
  14. Moler FW, Khan AS, Meliones JN, Custer JR, Palmisano J, Shope TC. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 1992;20:1406-13. https://doi.org/10.1097/00003246-199210000-00008
  15. Khongphatthanayothin A, Wong PC, Samara Y, Newth CJ, Wells WJ, Starnes VA, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med 1999;27:1974-81. https://doi.org/10.1097/00003246-199909000-00042
  16. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000;137:865-70. https://doi.org/10.1067/mpd.2000.110531
  17. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children: The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993;329:1524-30. https://doi.org/10.1056/NEJM199311183292102
  18. Simoes EA, Sondheimer HM, Top FH Jr, Meissner HC, Welliver RC, Kramer AA, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr 1998;133:492-9. https://doi.org/10.1016/S0022-3476(98)70056-3
  19. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112(6 Pt 1):1442-6. https://doi.org/10.1542/peds.112.6.1442
  20. Zachariah P, Ruttenber M, Simoes EA. Hospitalizations due to respiratory syncytial virus in children with congenital malformations. Pediatr Infect Dis J 2011;30:442-5. https://doi.org/10.1097/INF.0b013e318201813b
  21. Zachariah P, Simoes EA. Respiratory syncytial virus infection and congenital heart disease. South Afr J Epidemiol Infect 2008;23:17-9.
  22. Saji T, Nakazawa M, Harada K. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.Pediatr Infect Dis J 2008;27:1108-9. https://doi.org/10.1097/INF.0b013e3181801d76
  23. Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol Young 2005;15:251-5. https://doi.org/10.1017/S1047951105000533
  24. Feltes TF, Sondheimer HM. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin Biol Ther 2007;7:1471-80. https://doi.org/10.1517/14712598.7.9.1471
  25. Chang RK, Chen AY. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease. Pediatr Cardiol 2010;31:90-5. https://doi.org/10.1007/s00246-009-9577-0
  26. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 2004;89:961-5. https://doi.org/10.1136/adc.2003.046714
  27. Shim WS, Lee JY, Song JY, Lim SJ, Kim SH, Jang SI, et al. Respiratory syncytial virus infection cases in congenital heart disease patients. Korean J Pediatr 2010;53:380-91. https://doi.org/10.3345/kjp.2010.53.3.380

피인용 문헌

  1. Clinical and epidemiologic profile of lower respiratory tract infections associated with human bocavirus vol.48, pp.11, 2011, https://doi.org/10.1002/ppul.22732
  2. Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab vol.28, pp.2, 2013, https://doi.org/10.1097/hco.0b013e32835dce2f
  3. Pediatric Pulmonary Hypertension : Guidelines From the American Heart Association and American Thoracic Society vol.132, pp.21, 2011, https://doi.org/10.1161/cir.0000000000000329
  4. Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases vol.46, pp.5, 2011, https://doi.org/10.4070/kcj.2016.46.5.719
  5. Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses vol.12, pp.3, 2017, https://doi.org/10.1371/journal.pone.0172512
  6. Respiratory syncytial virus: an overview of infection biology and vaccination strategies vol.12, pp.5, 2017, https://doi.org/10.2217/fvl-2017-0120
  7. CHD and respiratory syncytial virus: global expert exchange recommendations vol.27, pp.8, 2011, https://doi.org/10.1017/s1047951117000609
  8. Influence of the type of congenital heart defects on epithelial lining fluid composition in infants undergoing cardiac surgery with cardiopulmonary bypass vol.83, pp.4, 2018, https://doi.org/10.1038/pr.2017.326
  9. New mouse model of pulmonary hypertension induced by respiratory syncytial virus bronchiolitis vol.315, pp.3, 2011, https://doi.org/10.1152/ajpheart.00627.2017
  10. Respiratory virus prophylaxis in congenital heart disease vol.14, pp.5, 2011, https://doi.org/10.2217/fca-2017-0096
  11. Respiratory syncytial virus infection in cardiac patients: outcomes preordained by IL-6 gene polymorphism? vol.71, pp.2, 2011, https://doi.org/10.23736/s0026-4946.18.05236-2
  12. Pulmonary hypertension during respiratory syncytial virus bronchiolitis: a risk factor for severity of illness vol.29, pp.5, 2019, https://doi.org/10.1017/s1047951119000313
  13. Respiratory syncytial virus infection: why does disease severity vary among individuals? vol.14, pp.4, 2011, https://doi.org/10.1080/17476348.2020.1724095
  14. Impact of pulmonary hypertension and congenital heart disease with hemodynamic repercussion on the severity of acute respiratory infections in children under 5 years of age at a pediatric referral cen vol.30, pp.12, 2011, https://doi.org/10.1017/s1047951120002991